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3Overview
 Background
 Safety monitoring update
from the Vaccine Adverse Event Reporting System (VAERS)
 Rapid Cycle Analysis (RCA)
from the Vaccine Safety Datalink (VSD)
 FDA assessment of Guillain-Barré syndrome following influenza vaccine
from Medicare data
 Clinical research studies in progress
from the Clinical Immunization Safety Assessment (CISA) Project 
4Vaccine safety monitoring and research terms
Term Explanation
Adverse event An adverse medical or health event following vaccination (a temporally associated event), which may or may not be related to vaccination (i.e., coincidental).
Adverse reaction An adverse health event following vaccination where substantial evidence exists to suggest the event is causally related to vaccination. 
MedDRA A clinically-validated international medical terminology used by regulatory authorities to describe health outcomes and events.
ICD-10 and 9 A system used by physicians and other healthcare providers to classify and code diagnoses, symptoms and procedures associated with healthcare.
Automated analysis Analysis on administrative or claims data or non-chart/health record confirmed data.
Chart confirmed/ 
medical record 
confirmed case
A case where review of medical charts and records by physicians or medical personnel confirms the 
diagnosis as valid and with accurate onset relative to timing of vaccination. 
Incident case A new case occurring for the first time ever or during a specified time period.
Prevalent or non-
incident case
A case that has been diagnosed in the past prior to vaccination or prior the study period that has 
become part of the patient’s past medical history and therefore is not new.
Biologically plausible 
risk interval
The time interval following vaccination where it is biologically plausible, based on the best available 
science, that an observed adverse event could be related to vaccination.
Statistical signal
A finding from an analysis where a calculated value (i.e., the test statistic) exceeds a specified statistical 
threshold; a statistical signal does not necessarily represent a vaccine safety problem and requires 
further assessment before conclusions can be drawn.
51IIV is commonly used when discussing inactivated influenza vaccines as a general category
Influenza vaccine abbreviations1
Abbreviation Vaccine
IIV3, IIV4 Trivalent  and quadrivalent inactivated influenza vaccine
IIV3-HD High-dose trivalent inactivated influenza vaccine(approved for use in individuals 65+ years old)
ccIIV4 Cell culture-based quadrivalent inactivated influenza vaccine
RIV4 Recombinant quadrivalent influenza vaccine 
aIIV3 Adjuvanted trivalent inactivated influenza vaccine(approved for use in individuals 65+ years old)
LAIV4 Quadrivalent live attenuated influenza vaccine 
Safety monitoring update
from the Vaccine Adverse Event Reporting System (VAERS)
7Co-managed by
CDC and FDA
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Adverse
Event 
Reporting 
System
http://vaers.hhs.gov
8Vaccine Adverse Event Reporting System (VAERS)
Strengths
 National data 
 Accepts reports from anyone
 Rapidly detects safety signals 
 Can detect rare adverse events
 Data available to public
Limitations
 Reporting bias 
 Inconsistent data quality and 
completeness
 Lack of unvaccinated comparison group
 Generally cannot assess causality
• VAERS accepts all reports from all reporters without making judgments on 
causality, irrespective of clinical seriousness
• As a hypothesis generating system, VAERS identifies potential vaccine safety 
concerns that can be studied in more robust data systems
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 U.S. influenza vaccine reports from July 2018-April 2019 (as of May 10, 2019)
 Signs, symptoms, and diagnoses coded using Medical Dictionary for 
Regulatory Activities (MedDRA) terms
 Clinical review of reports (includes medical records when available):
• All serious1 reports
• Pregnancy reports for spontaneous abortion, stillbirth, congenital anomalies
• Anaphylaxis reports in persons with a history of egg allergy
 Empirical Bayesian data mining to detect disproportional reporting for 
vaccine-adverse event pairings
1Based on the Code of Federal Regulations if one of the following is reported: death, life-threatening illness, hospitalization or prolongation of 
hospitalization, permanent disability, congenital anomaly or birth defect (FDA routinely reviews all serious reports)
VAERS monitoring: methods
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 No data mining signals for Guillain-Barré syndrome, anaphylaxis, or febrile 
convulsion in association with IIV3, IIV4 or IIV3-HD
1U.S. primary reports (foreign reports excluded), all ages; 2Based on the Code of Federal Regulations if one of the following is reported: death, life-threatening illness, hospitalization or 
prolongation of hospitalization, permanent disability, congenital anomaly or birth defect; 3Onset interval 0-1 days post vaccination for anaphylaxis; 4 No anaphylaxis reports in persons with a 
history of egg allergy; 5Limited to reports in children aged 6-59 months old
Reports by vaccine type, 2018-2019 influenza season
IIV3
N (%)
IIV4
N (%)
IIV3-HD
N (%)
Total reports1 150 4,890 2,169
Non-serious reports 141 (94%) 4,621 (94%) 2,076 (96%)
Serious reports2 9 (6%) 269 (6%) 93 (4%)
Guillain-Barré syndrome (GBS) 2 (1.3%) 33 (0.7%) 13 (0.6%)
Anaphylaxis3 0 (0%) 244 (0.5%) 24 (0.1%)
Febrile convulsion5 1 (0.7%) 25 (0.5%) ---
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1U.S. primary reports (foreign reports excluded), all ages; 2Based on the Code of Federal Regulations if one of the following is reported: death, life-threatening illness, hospitalization or prolongation of 
hospitalization, permanent disability, congenital anomaly or birth defect; 3Onset interval 0-1 days post vaccination for anaphylaxis; 4 One ccIIV4 anaphylaxis report in a person with a history of egg allergy. 
No anaphylaxis reports in persons with a history of egg allergy for aIIV3, RIV4, or LAIV; 5Limited to reports in children aged 6-59 months old
 No data mining signals for Guillain-Barré syndrome, anaphylaxis, or febrile convulsion 
in association with ccIIV4, aIIV3, RIV4, or LAIV4
Reports by vaccine type, 2018-2019 influenza season
ccIIV4
N (%)
aIIV3
N (%)
RIV4
N (%)
LAIV4
(N%)
Total reports1 1,040 708 276 23
Non-serious reports 1,007 (97%) 692  (98%) 268 (97%) 22 (96%)
Serious reports2 33 (3%) 16 (2%) 8 (3%) 1 (4%)
Guillain-Barré syndrome (GBS) 16 (1.5%) 1 (0.1%) 4 (1.4%) 0 (0%)
Anaphylaxis3 34 (0.3%) 14 (0.1%) 14 (0.4%) 0 (0%)
Febrile convulsion5 0 (0%) --- --- 0 (0%)
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Reports involving vaccination during pregnancy, 2018-2019
Total reports (IIV4=55, ccIIV4=67, IIV3=4, RIV4=6, unknown type/brand=9) 1411
Median maternal age (range) at vaccination 32 years (16-43)
Median gestational age (range) at vaccination, n=117 with GA reported 21 weeks (1-41)
Trimester of vaccination, n=117 reports with trimester documented
• 1st trimester
• 2nd trimester
• 3rd trimester
36 (31%)
44 (38%)
37 (32%)
Pregnancy-specific adverse event reports
Spontaneous abortion (13), preterm delivery (9), premature labor (6), stillbirth (2), 
pre-eclampsia (2), oligohydramnios (2), placenta previa (2), dysmature placenta (2), 
premature rupture of membranes (1), gestational hypertension (1), gestational 
diabetes (1), placentae abruption (1), vaginal discharge (1), nausea (1)
44 (31%)
Non-pregnancy specific adverse event reports 43 (30%)
Infant or fetal adverse event2 18 (13%)
No adverse event documented in report 38 (27%) 
1141 reports described 143 adverse events (two reports described adverse events in mother and infant); 2Low birth weight (5), large for gestational age (2), meconium in amniotic 
fluid (2), nuchal chord (1), hypospadias and chyothorax (1), dystocia of shoulder (1), intrauterine growth retardation (1), jaundice (1), tricuspid regurgitation and pulmonary 
insufficiency (1), upper respiratory tract infection, (1), cystic fibrosis carrier (1), asymmetrical growth (1)
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 No new safety concerns detected for IIV3, IIV4, LAIV4, IIV3-HD, ccIIV4, 
aIIV3, or RIV4 during the 2018-2019 influenza season
 Surveillance for the 2019-2020 influenza season will include enhanced 
safety monitoring1 for:
• aIIV3 (FLUAD®)
• RIV4 (Flublok® Quadrivalent)
• Pregnancy reports
• Anaphylaxis reports in persons with history of egg allergy 
1Includes clinical review of all reports and available medical records for the specific vaccines and outcomes and conditions specified
Summary of VAERS monitoring
Rapid Cycle Analysis (RCA)
from the Vaccine Safety Datalink (VSD)
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Vaccine
Safety
Datalink
8 participating integrated 
healthcare organizations
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Vaccine Safety Datalink (VSD)
 Established in 1990 
 Collaboration between CDC and several integrated 
healthcare organizations 
 Medical care and demographic data on over 12.1 million 
persons per year (~3.7% of U.S. population)
 Links vaccination data to health outcome data
 Used for surveillance and research
17
VSD electronic files + chart review 
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Influenza vaccine Rapid Cycle Analysis (RCA) in the VSD
*Each patient serves as his/her own control, looking at events in risk window and events in comparison window
†Looking at events in risk window in patients in current season versus patients during historical comparison period 
 Weekly near real-time 
sequential monitoring 
to detect statistical 
signals for pre-
specified outcomes
 Includes methods to 
adjust for sequential 
testing
 Focused on standard 
dose IIV4 and IIV3 
High-Dose
 Uptake of other 
influenza vaccine 
products is still 
relatively low in VSD
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A powerful and sophisticated tool
 Near real-time vaccine-safety monitoring (using sequential monitoring techniques)
 Employs an automated analysis that uses ICD-coded diagnoses from administrative data
 A surveillance activity (signal detection and signal refinement), which is not the same as an 
epidemiologic study (signal evaluation, causality assessment)
 Requires careful thought and customization in the design, set-up, interpretation
Designed to detect statistical signals (values above specified statistical thresholds)
 When a statistical signal occurs, CDC conducts a series of evaluations using traditional 
epidemiologic methods
 Chart-confirmation of diagnoses to confirm or exclude cases as true incident cases is a key 
part of statistical signal assessment 
Not all statistical signals represent a true increase in risk for an adverse event
Rapid Cycle Analysis (RCA) in VSD
20201For self-controlled risk interval design
RCA outcomes for the 2018-2019 influenza season
Pre-specified outcome Age group Risk window(days)
Comparison window1
(days)
Acute disseminated 
encephalomyelitis (ADEM)
>6 mo 1-21 -56 to -15
Anaphylaxis >6 mo 0-2 7-9
Bell’s palsy
>6 mo to <18 yr
18-49 yr
>50 yr
1-42 -56 to -15
Encephalitis >6 mo 1-21 -56 to -15
Guillain-Barré syndrome (GBS) >6 mo 1-42 43-84
Seizures 6-23 mo24-59 mo 0-1 14-20
Transverse myelitis >6 mo 1-21 -56 to -15
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1Doses administered through April 3, 2019; percentages subject to rounding errors
Influenza vaccine dose 1 doses administered in 2018-2019
Vaccine Dose 1 doses administered
1
all ages
IIV4 3,898,542 (71%)
IIV3 High-Dose 645,362 (12%)
ccIIV4 510,010 (9%)
aIIV3 27,177 (0.5%)
RIV4 374,996 (7%)
Total 5,456,087
22221Doses administered through April 3, 2019; percentages subject to rounding errors
Influenza vaccine RCA – summary of statistical signals
Current vs. historical design Self-controlled risk interval design
Pre-specified 
outcomes
Risk 
interval
Age 
group IIV4 ccIIV4 IIV3-HD IIV4 ccIIV4 IIV3-HD
ADEM 1-21 ≥6 mo
Anaphylaxis 0-2 ≥6 mo
Yes
10/21/18
Yes (≥4 yr)
11/11/18
Yes (≥4 yr)
12/9/18
Bell's Palsy 1-42
<18 yr
Yes (4-17 yr)
12/9/18
18-49 yr
≥50 yr
Encephalitis 1-21 ≥6 mo
GBS 1-42 ≥6 mo
Yes (65+)
12/9/18
Seizures 0-1 6-23 mo
Yes
11/25/18
24-59 mo
Yes
12/9/18
Yes
11/4/18
Transverse myelitis 1-21 ≥6 mo
Anaphylaxis
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 For end-of-season analysis, chart reviewed 18 potential cases (9 additional cases)
• 11 had symptom onset prior to vaccination (i.e., other exposures and vaccinated in ED)
• 6 had onset post vaccination but with other exposures to explain anaphylaxis: foods (3), 
medications (2), exercise induced (1) 
• 1 case determined to be potentially vaccine related: patient received IIV4 and 
recombinant zoster vaccine simultaneously
 Signal assessment: after chart review, observed rate of 0.26 cases/1 million 
vaccinated, which is below published VSD rate of 1.6 cases/1 million vaccinated
Statistical signal week of Oct 21, 2018 for anaphylaxis 
following IIV4 in current vs. historical analysis
Risk 
interval Age group
Vaccine 
doses
Observed 
# events
Expected 
# events RR
Log likelihood 
ratio (LLR)
Critical value 
of LLR
0-2 days ≥6 months 1,880,068 9 3.119 2.88 3.66 3.0
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 For end-of-season analysis, chart reviewed 7 potential cases (3 additional cases)
 Signal assessment: after adjudication, 0 cases were determined to be related to 
vaccine
• Most had symptoms prior to vaccination and other exposures included codeine, 
naproxen, milk, and gentamicin
Statistical signal week of Nov 11, 2018 for anaphylaxis
following ccIIV4 in current vs. historical analysis*
Risk interval Age group
Vaccine 
doses
Observed 
# events
Expected 
# events RR
Log likelihood 
ratio (LLR)
Critical value 
of LLR
0-2 days ≥4 years 342,965 4 0.526 7.61 4.64 3.06
*Self-controlled risk interval analysis (that signaled Dec 9, 2019) included the same exposed cases as in the current vs. historical analysis
Bell’s palsy
2727
Statistical signal week of Dec 9, 2018 for Bell’s palsy 
following ccIIV4 in self-controlled risk interval analysis
Risk 
interval
Age 
group
Vaccine 
doses
Events in risk 
window 
(1 to 42d)
Events in 
comparison window
(-56 to -15d)
RR
Log 
likelihood 
ratio (LLR)
Critical 
value of
LLR
1-42 days 4-17 yr 45,453 4 1 4 4.3944 3.4657
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 Chart confirmed self-controlled risk interval (SCRI) analysis:
• Risk window
‒
‒
‒
cases chart review (n=4)
1 case had an initial diagnosis of Bell’s palsy, later determined that symptoms were 
related to acute otitis media (on day 4 after vaccination)
3 cases determined to be Bell’s palsy with symptom onset in risk window
• Comparison window case chart review (n=1)
1 case determined to be Bell’s palsy with symptom onset 55 days prior to vaccination
• Final chart reviewed SCRI signal assessment: 3 cases in risk window, 1 case in 
comparison window, RR=3.0 (95% CI: 0.31-28.8)
 Current vs. historical analysis using automated data: 4 observed cases, 1.51 
expected cases, RR=2.65, LLR=1.41, critical value of LLR=3.99
Assessment of statistical signal for Bell’s palsy 
following ccIIV4
Seizures
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Statistical signal week of Nov 25, 2018 for seizures
following IIV4 in self-controlled risk interval analysis
Children aged 6-23 months old
Risk 
interval
Age 
group
vaccine 
doses
Events in risk 
window 
(0-1d)
Events in 
comparison window
(14-20d)
RR
Log 
likelihood 
ratio (LLR)
Critical 
value of
LLR
0-1 days 6-23 months 93,892 10 11 3.18 3.273 3.0082
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Statistical signal for seizures following IIV4
Children aged 24-59 months old
Risk 
interval
Age 
group
vaccine 
doses
Events in risk 
window 
(0-1d)
Events in 
comparison window
(14-20d)
RR
Log 
likelihood 
ratio (LLR)
Critical 
value of
LLR
0-1 days 24-59 months 106,853 8 4 6.125 4.3235 3.0082
Self-controlled risk interval analysis: statistical signal week of Nov 4, 2018
Risk 
interval
Age 
group
vaccine 
doses
Obs. # 
events
Exp. # 
events RR
Log likelihood 
ratio (LLR)
Critical value 
of LLR
0-1 days 24-59 months 151,826 11 4.80 2.29 2.91 2.87
Current vs. historical analysis: statistical signal week of Dec 9, 2018
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Age group
Events in 
risk window 
(0-1 days)
Events in 
comparison 
window 
(14-20 days)
Incidence rate 
ratio
IRR (95% CI)
Attributable
risk per 
100,000 doses 
administered
6-23 months 11 16 2.41 (1.12-5.18) 4.24
24-59 months 5 5 3.50 (1.01-12.09) 1.80
Vaccines (in 6-59 mo)
IIV4 alone 6 9 2.33 (0.83-6.56) 1.60
IIV4 w/any other vax 10 12 2.92 (1.26-6.75) 4.84
IIV4 w/PCV13 5 7 2.50 (0.79-7.88) 4.73
Seizures: final self-controlled risk interval (SCRI) 
analysis using chart confirmed cases of febrile seizure
Guillain-Barré Syndrome (GBS)
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Statistical signal week of Dec 9, 2018 for Guillain-Barré
Syndrome following IIV3 high-dose in SCRI analysis
Risk 
interval
Age 
group
Vaccine 
doses
Events in risk 
window 
(1-42d)
Events in 
comparison window
(43-84d)
RR*
Log 
likelihood 
ratio (LLR)
Critical 
value of
LLR
1-42 days ≥65 years 614,200 5 0 11 3.4657 3.3914
Self-controlled risk interval analysis: statistical signal week of Dec 9, 2018
Risk 
interval
Age 
group
Vaccine 
doses
Events in risk 
window 
(1-42d)
Events in 
comparison window
(43-84d)
RR
Log 
likelihood 
ratio (LLR)
Critical 
value of
LLR
1-42 days ≥65 years 645,362 8 1 8 --- ---
Last self-controlled risk interval analysis: Apr 3, 2019
*When denominator is 0, 0.5 is added to both numerator and denominator to estimate relative risk
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 Chart reviews and adjudication
• Risk window (n=8): 1 GBS case classified as Brighton Collaboration Level 2
‒ Other 7 GBS cases ruled out as prevalent/non-incident cases, alternate diagnoses, 
symptom onset prior to or on day of vaccination, lack of clinical evidence
• Comparison window (n=1): 1 GBS case classified as Brighton Collaboration Level 1
• After case adjudication (above), RR=1.0 comparing 1 case in the risk window to 1 
case in the comparison window
 No statistical signal has been observed by Apr 3, 2019 for the corresponding 
current vs. historical analysis
• RR=1.60, LLR=0.76, critical value of LLR=3.03
Assessment of statistical signal for Guillain-Barré
Syndrome (GBS) following IIV3 high-dose
FDA assessment of Guillain-Barré 
syndrome following influenza vaccine
from Medicare data
FDA/CDC/CMS analysis of Guillain-Barré syndrome 
risk following influenza vaccine
Slides courtesy Rich Forshee, PhD
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FDA/CDC/CMS Analysis of GBS Risk: Methods
• FDA conducted a self-controlled risk interval (SCRI) analysis with an 8-21 
day risk interval for the association between influenza vaccines and GBS
• Data source was Medicare claims for recipients 65+y
• This was an early vaccination cutoff analysis that included beneficiaries 
vaccinated between August 11, 2018 and November 9, 2018
• Included more than 12 million beneficiaries in total; more than 7 million 
who received IIV3-HD 
• An end-of-season analysis is planned
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FDA/CDC/CMS Analysis of GBS Risk: Results
• Highest point estimate was for IIV3-HD
–
–
–
–
–
16 cases in 8-21 day risk interval; 26 cases in 43-84 day control interval
Odds ratio = 1.85 (95% CI 0.99, 3.44; p-value = 0.054)
Attributable risk = 0.98 per million vaccinations
Magnitude of the odds ratio is similar to what has been observed in 
previous seasons
Attributable risk is consistent with the labeled risk of GBS
Summary
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 Following signal assessment and end-of-season analysis:
• Statistical signals for anaphylaxis following IIV4 and ccIIV4 ruled out
• Finding of an elevated risk for Bell’s palsy following ccIIV4 in 4-17 year olds 
(RR=3.0, 95% CI 0.31-28.8) was based on a small number of cases and doses; 
CDC will continue to monitor and explore options for additional analyses
‒ 2001-2006 case-centered analysis with IIV3 did not find an association2
• Statistical signal for GBS following IIV3-HD (65+ years old) ruled out
• Preliminary FDA analysis of GBS following IIV3-HD in CMS data indicate that 
the risk, if any, is no greater than in some previous seasons and consistent 
w/labeled risk of GBS
Summary of VSD RCA monitoring for influenza 
vaccine, 2018-20191
1Including FDA analysis of GBS and IIV3-HD; 2Rowhani-Rahbar et al. Immunization and Bell's palsy in children: a case-centered analysis. Am J Epidemiol. 2012;175(9):878-85.
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 Final self-controlled risk interval (SCRI) analysis of confirmed 
febrile seizure cases showed:
• An elevated IRR in children aged 6-23 and 24-59 months
• Risk was similar in those who received IIV4 alone and those who received 
IIV4 simultaneously with other vaccines, including PCV13
‒ In some previous seasons risk was greater with simultaneous PCV13
• Attributable risk was less than that observed in some previous influenza 
seasons and less than the febrile seizure risk associated with MMR or PCV
Summary of VSD RCA monitoring for influenza 
vaccine, 2018-2019 (cont.) 
Clinical Research Studies in Progress
from the Clinical Immunization Safety Assessment (CISA) Project
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Clinical
Immunization
Safety
Assessment
 assist U.S. healthcare 
providers with complex 
vaccine safety questions 
about their patients
CISAeval@cdc.gov†
 conduct clinical research
Vaccine safety monitoring
vaccine safety experts 
7 participating medical 
research centers*
*Boston Medical Center, MA; Cincinnati Children’s Hospital 
Medical Center, OH; Columbia University, NY; Duke University, 
NC; Johns Hopkins University, MD; Kaiser Permanente Northern 
California, CA; Vanderbilt University TN 
†More information about clinical consults available at: 
http://www.cdc.gov/vaccinesafety/Activities/CISA.html
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Current CISA influenza vaccine studies
Title (ClinicalTrials.gov number)
Enrollment 
completed
(influenza season)
CISA Study Sites
Safety and immunogenicity of simultaneous Tdap and IIV 
in pregnant women (NCT02783170)
Yes*
(2016-17 & 2017-18) 
Duke University (lead), Cincinnati  
Children’s Hospital Medical Center
Safety of LAIV4 in children with asthma (NCT03600428 
and NCT02967393) No
Vanderbilt University (lead),
Cincinnati  Children’s Hospital 
Medical Center, Duke University 
Adjuvanted versus high-dose IIV in older adults 
(NCT03183908)
Yes
(2017-18 & 2018-19)
Duke University  (lead), Boston 
Medical Center, Cincinnati  
Children’s Hospital Medical Center‡
Fever after simultaneous versus sequential vaccination in 
young children (NCT03165981)
Yes*
(2017-18) 
Duke University, Kaiser Permanente 
Northern California 
Safety of quadrivalent recombinant influenza vaccine 
(RIV4) (Flublok® Quadrivalent) vs IIV4 (Flublok®) in 
pregnant women (NCT03969641)
No Duke University (lead), Cincinnati  Children’s Hospital Medical Center, 
Boston Medical Center 
*Results posted on ClinicalTrials.gov  ‡Cincinnati Children’s Hospital Medical Center site is supported via a sub-contract with Boston Medical Centers for this study 
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